Today’s Market Runner: Sangamo Biosciences, Inc.’s Stock Is Sell After Today’s Significant Decline

Today's Market Runner: Sangamo Biosciences, Inc.'s Stock Is Sell After Today's Significant Decline

The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) is a huge mover today! About 683,351 shares traded hands. Sangamo Biosciences, Inc. (NASDAQ:SGMO) has declined 19.93% since March 3, 2016 and is downtrending. It has underperformed by 28.28% the S&P500.
The move comes after 8 months negative chart setup for the $311.43M company. It was reported on Oct, 6 by Barchart.com. We have $3.79 PT which if reached, will make NASDAQ:SGMO worth $43.60 million less.

Analysts await Sangamo Biosciences, Inc. (NASDAQ:SGMO) to report earnings on October, 26. They expect $-0.25 earnings per share, down 92.31% or $0.12 from last year’s $-0.13 per share. After $-0.38 actual earnings per share reported by Sangamo Biosciences, Inc. for the previous quarter, Wall Street now forecasts -34.21% EPS growth.

Sangamo Biosciences, Inc. (NASDAQ:SGMO) Ratings Coverage

Out of 7 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 5 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 71% are positive. Sangamo Biosciences has been the topic of 9 analyst reports since August 8, 2015 according to StockzIntelligence Inc. As per Tuesday, September 8, the company rating was downgraded by Zacks. On Friday, September 4 the stock rating was maintained by Cowen & Co with “Buy”. The company was reinitiated on Friday, October 23 by Jefferies. On Wednesday, September 2 the stock rating was maintained by Jefferies with “Buy”. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) has “Buy” rating given on Wednesday, September 2 by Wedbush. Janney Capital downgraded the shares of SGMO in a report on Thursday, August 4 to “Neutral” rating. JP Morgan maintained the stock with “Overweight” rating in Saturday, August 8 report. The stock of Sangamo Biosciences, Inc. (NASDAQ:SGMO) earned “Outperform” rating by Wells Fargo on Friday, December 4. The rating was maintained by JP Morgan on Thursday, September 3 with “Buy”.

According to Zacks Investment Research, “Sangamo BioSciences, Inc. is a leader in the development of novel transcription factors for the regulation of gene expression. Transcription factors are proteins that turn genes on or off by recognizing specific DNA sequences. The Universal Gene Recognition technology platform enables the engineering of a class of transcription factors known as zinc finger DNA binding proteins.”

Insitutional Activity: The institutional sentiment decreased to 0.81 in 2016 Q2. Its down 0.57, from 1.38 in 2016Q1. The ratio turned negative, as 20 funds sold all Sangamo Biosciences, Inc. shares owned while 42 reduced positions. 13 funds bought stakes while 37 increased positions. They now own 45.72 million shares or 4.72% less from 47.99 million shares in 2016Q1.
Invesco Limited last reported 23,513 shares in the company. D E Shaw & owns 113,406 shares or 0% of their US portfolio. Moreover, California Employees Retirement Sys has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 127,500 shares. Bnp Paribas Arbitrage has 2,727 shares for 0% of their US portfolio. Iguana Healthcare Mngmt Llc last reported 0.29% of its portfolio in the stock. Rhumbline Advisers has invested 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO). Teachers Advsrs holds 157,035 shares or 0% of its portfolio. Princeton Incorporated last reported 124,395 shares in the company. Baldwin Brothers Ma holds 0% or 1,500 shares in its portfolio. Connor Clark & Lunn Management owns 163,709 shares or 0.01% of their US portfolio. Northern holds 879,456 shares or 0% of its portfolio. Highlander Mgmt Limited Liability Co accumulated 43,000 shares or 0.23% of the stock. Blackrock Institutional Co Na last reported 0% of its portfolio in the stock. Pnc Serv Grp Inc holds 0% of its portfolio in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 432 shares. Moreover, Swiss Fincl Bank has 0% invested in Sangamo Biosciences, Inc. (NASDAQ:SGMO) for 113,560 shares.

More notable recent Sangamo Biosciences, Inc. (NASDAQ:SGMO) news were published by: Fool.com which released: “Why Sangamo Biosciences, Inc. Fell 29% Today” on August 04, 2016, also Prnewswire.com with their article: “Sangamo BioSciences Announces Retirement Of Edward Lanphier As President And …” published on June 01, 2016, Prnewswire.com published: “Sangamo BioSciences Announces Second Quarter 2016 Conference Call and Webcast” on July 27, 2016. More interesting news about Sangamo Biosciences, Inc. (NASDAQ:SGMO) were released by: Prnewswire.com and their article: “Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX …” published on September 06, 2016 as well as Prnewswire.com‘s news article titled: “Sangamo BioSciences Announces New Gene Therapy Clinical Development Program …” with publication date: July 26, 2016.

SGMO Company Profile

Sangamo Biosciences Inc., incorporated on June 22, 1995, is a clinical-stage biopharmaceutical company. The Firm is focused on the research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. The Firm is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics, which are therapeutic products for the treatment of genetic disease. The Company’s ZFP Therapeutic, SB-728, a ZFP nuclease (ZFN)-modified autologous cell product for the treatment of Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS), is the therapeutic application of its ZFN genome editing technology and is being evaluated in an ongoing Phase II study of ZFN-modified T-cells (SB-728-T-1101, Cohort 3) and a Phase I/II study of modified hematopoietic stem cells (SB-728mR-HSPC) in HIV-infected subjects. The Firm has preclinical programs in hemophilia A and other Lysergic acid diethylamide (LSDs), and research stage programs in other monogenic diseases, including certain central nervous system (CNS) disorders and cancer immunotherapy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment